Full Press Release Details
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial
Evaluating Bempikibart in Patients with
Alopecia Areata at the 2025 American Academy of Dermatology Meeting
Results presented in AAD late-breaker demonstrate bempikibart s encouraging improvement on SALT
reduction at week 24 and continued effects after dosing cessation in patients with severe and very
severe alopecia areata (AA)
Durable, ongoing responses in multiple patients through week 36 follow-up period and beyond to
week 55, despite only 24 weeks of dosing, suggestive of potential for remittive effect; multiple inbound
patient requests to re-initiate dosing
In the Phase 2a clinical trial, bempikibart was observed to be safe and well-tolerated, with PK
supporting subcutaneous dosing and receptor occupancy data demonstrating desired target
engagement; clinical biomarkers showed changes in Th2 biomarkers, and expected on-mechanism
changes in T-cells, indicative of potent IL-7 and TSLP
Bempikibart development program remains on track with open-label extension study to initiate in
1H 25; SIGNAL-AA Part B remains on track for initiation of dosing in 1H 25, with topline
WALTHAM, Mass. March 8, 2025 Q32 Bio Inc. (Nasdaq: QTTB) ( Q32 Bio ), a clinical stage biotechnology company
focused on developing biologic therapeutics to restore immune homeostasis, today announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia
areata (AA) at the 2025 American Academy of Dermatology (AAD) Meeting in Orlando, FL. Bempikibart is a fully human anti-IL-7R antibody that re-regulates adaptive immune function by blocking IL-7 and TSLP signaling that is in development for the treatment of AA and currently being evaluated in a Phase 2 program.
We are excited to share the results from our late-breaker at AAD which includes completed 36-week data and
extended follow-up of patients in long-term response who voluntarily re-consented for further assessments based on their maintenance or further deepening of responses
after the end of the trial, said Jodie Morrison, Chief Executive Officer of Q32 Bio. These findings demonstrate for the first time in patients the potential of an IL-7R antagonist approach to
deliver durable and sustained activity and recapitulate over a decade of nonclinical research highlighting the potential of this type of sustained response in multiple animal disease models. Given these exciting findings, we have committed to
advancing bempikibart as a potentially differentiated therapy for alopecia areata patients who have had limited treatment choices and, to date, no biologic option available.
The responses of patients with longstanding and severe disease, not only at 24 weeks but several weeks after treatment withdrawal, is very
provocative, said Brett King, M.D., Ph.D., of Dermatology Physicians of Connecticut, and former Associate Professor of Dermatology, Yale University School of Medicine. If the activity of bempikibart, including the potential to
induce a durable, long-term response, and the safety profile are confirmed in upcoming clinical trials, bempikibart has the potential to change the treatment paradigm of alopecia areata.
Results from SIGNAL-AA Part A Phase 2a Clinical Trial:
SIGNAL-AA Part A is a Phase 2a, randomized, double-blind, placebo-controlled, multi-center clinical trial evaluating
bempikibart in adult patients with severe and very severe AA (baseline Severity of Alopecia Tool (SALT) scores of 50-100) treated over 24 weeks, with follow-up through
36 weeks. The trial is being conducted to evaluate the efficacy and safety of bempikibart 200 mg administered subcutaneously (SC), every-other-week (Q2W) compared to placebo. SIGNAL-AA Part A comprised of 41
patients in the modified intent-to-treat population and 27 in the per protocol population, with a primary endpoint of the mean relative percent change in SALT score at
24 weeks compared with baseline, with follow-up in a 12-week post-treatment period through week 36. Additional data has been collected on patients after week 36, with follow-up on multiple patients through week 55 to date, and additional long-term follow-up ongoing.
Highlights on the per protocol basis from the 2025 AAD late-breaking presentation include:
During the on-treatment window:
During the post-treatment
Despite only 24 weeks of treatment across bempikibart treated patients, a deepening
response, as measured by mean SALT improvement, was observed following dosing cessation (week 24) through the post-treatment follow-up period (week 36), a paradigm believed to be associated with IL-7 on-mechanism modulation of rebalancing T effector memory cells and T regulatory function.
Additional post-treatment data collection
remains ongoing, including longer-term follow-up of patients following the completion of the trial (post 36 weeks). Outreach was made to patients regarding the post-treatment experience and patients willing to
participate were re-consented.
Bempikibart demonstrated a
well-tolerated safety and tolerability profile, with no Grade 3 or higher adverse events related to treatment. Further, no related viral infections were reported in the bempikibart group.
In addition, in the Phase 2a clinical trial, bempikibart at 200mg Q2W SC demonstrated favorable pharmacokinetics (PK) and target engagement as demonstrated by
substantial reductions in biomarkers of Th2 and expected modulation of T-cells. The reduction in Th2 biomarkers included TARC, IgE and eosinophils. CD3+ T-cells were reduced as expected with target engagement and IL-7R blockade. Q32 Bio believes these results demonstrate that bempikibart is a potent inhibitor of both
In addition to the meaningful mean SALT reductions through week 24, we observed deepening
responses throughout the follow-up period through week 36 and longer, despite dosing only through 24 weeks, including two patients with continued response at week 55, approximately seven months following
dosing cessation, said Jason Campagna, M.D., Ph.D., Chief Medical Officer of Q32 Bio. Our development program for bempikibart is designed to expand on these results, first with our open-label extension allowing for longer term dosing and
follow-up, and second, with SIGNAL-AA Part B which introduces a loading dosing regimen, longer dosing period and longer follow up.
SIGNAL-AA Part B is intended to support advancement into pivotal trials upon completion, pending review of the results.
Bempikibart Phase 2 Development Program:
Q32 Bio is advancing a comprehensive development program evaluating bempikibart in AA. Based on re-consent rates for
continued follow-up and strong interest from SIGNAL-AA Part A patients to re-initiate dosing, Q32 Bio plans to initiate an
open-label extension (OLE) following the same bempikibart dosing regimen leveraged in Part A to enable longer-term follow-up of patients. Initiation of the OLE remains on track for the first half of 2025.
In addition, Q32 Bio is advancing bempikibart in the Part B portion of the SIGNAL-AA Phase 2a clinical trial. SIGNAL-AA Part B is an open-label clinical trial, dosing patients with bempikibart for 36 weeks, with follow-up out to 52 weeks, in approximately 20 evaluable patients with
severe or very severe AA. Dosing will include an initial loading regimen of 200mg of bempikibart dosed weekly over four weeks, followed by a maintenance dose of 200mg every-other-week over a 32-week period for
a total of 36 weeks. Efficacy will be evaluated on the basis of mean percentage change from baseline in SALT scores as well as the proportion of subjects achieving various relative and absolute SALT improvements.at week 36, with follow-up through week 52. The trial is intended to support advancement into pivotal trials upon completion, pending review of the results. Q32 Bio expects to initiate Part B in the first half of 2025 and report
topline data in the first half of 2026.
A copy of the AAD late-breaking presentation is available on the Presentations and Publications page of Q32
clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases.
Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7R antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases, in a Phase 2 program. The
IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.
For more information, visit www.Q32Bio.com.
Other Information About Q32 Bio
Investors and others should note that we communicate with our investors and the public using our company website
www.Q32Bio.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly
Twitter) and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a
regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
This communication contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other
federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, our beliefs, observations, expectations and assumptions regarding the topline data from the
SIGNAL-AA Phase 2a and the safety, tolerability, clinical activity, potential efficacy and potential benefits of bempikibart; which involve risks and uncertainties that could cause actual results to differ
materially from those discussed in such forward-looking statements.
Forward-looking statements are based on management s current beliefs and
assumptions, which are subject to risks and uncertainties and are not guarantees of future performance. Such risks and uncertainties include, among others, the risk that additional data, or the results of ongoing data analyses, may not support our
current beliefs and expectations for bempikibart, including with respect to the durability of clinical responses, future clinical studies, including that the OLE may not be initiated by the first half of 2025 and that Part B of the SIGNAL-AA Phase 2a clinical trial may not be initiated by the first half of 2025, may not be completed by the first half of 2026 or at all, might be more costly than expected or might not yield anticipated results,
and such other risks and uncertainties identified in the Company s periodic, current and other filings with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the
quarter ended September 30, 2024 and any subsequent filings with the Commission, which are available at the SEC s website at www.sec.gov. Any such risks and uncertainties could materially and adversely affect the Company s results of
operations and its cash flows, which would, in turn, have a significant and adverse impact on the Company s stock price. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are
made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood
that actual results will differ from those set forth in the forward-looking statements.
Investors: Brendan Burns